These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15718101)

  • 1. PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas.
    Johnstone CN; Castellví-Bel S; Chang LM; Sung RK; Bowser MJ; Piqué JM; Castells A; Rustgi AK
    Genomics; 2005 Mar; 85(3):338-51. PubMed ID: 15718101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers.
    Johnstone CN; Castellví-Bel S; Chang LM; Bessa X; Nakagawa H; Harada H; Sung RK; Piqué JM; Castells A; Rustgi AK
    Gene; 2004 Jul; 336(1):59-71. PubMed ID: 15225876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic organization and structure of the 5'-flanking region of the TEX101 gene: alternative promoter usage and splicing generate transcript variants with distinct 5'-untranslated region.
    Tsukamoto H; Takizawa T; Takamori K; Ogawa H; Araki Y
    Mol Reprod Dev; 2007 Feb; 74(2):154-62. PubMed ID: 16941676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines.
    Mayer K; Ballhausen WG
    Anticancer Res; 1996; 16(4A):1733-7. PubMed ID: 8712692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines.
    Wong NA; Britton MP; Choi GS; Stanton TK; Bicknell DC; Wilding JL; Bodmer WF
    Proc Natl Acad Sci U S A; 2004 Jan; 101(2):574-9. PubMed ID: 14704280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.
    Vitale L; Frabetti F; Huntsman SA; Canaider S; Casadei R; Lenzi L; Facchin F; Carinci P; Zannotti M; Coppola D; Strippoli P
    BMC Cancer; 2007 Apr; 7():66. PubMed ID: 17442112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of GATA3 in human breast tumors.
    Usary J; Llaca V; Karaca G; Presswala S; Karaca M; He X; Langerød A; Kåresen R; Oh DS; Dressler LG; Lønning PE; Strausberg RL; Chanock S; Børresen-Dale AL; Perou CM
    Oncogene; 2004 Oct; 23(46):7669-78. PubMed ID: 15361840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic analysis of the putative tumor suppressor km23 in primary ovarian, breast, and colorectal cancers.
    Campbell IG; Phillips WA; Choong DY
    Clin Cancer Res; 2006 Jun; 12(12):3713-5. PubMed ID: 16778097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
    Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
    Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
    Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
    Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.
    Sekine I; Sato M; Sunaga N; Toyooka S; Peyton M; Parsons R; Wang W; Gazdar AF; Minna JD
    Oncogene; 2005 Apr; 24(16):2735-8. PubMed ID: 15735765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative promoter usage and alternative splicing contribute to mRNA heterogeneity of mouse monocarboxylate transporter 2.
    Zhang SX; Searcy TR; Wu Y; Gozal D; Wang Y
    Physiol Genomics; 2007 Dec; 32(1):95-104. PubMed ID: 17911380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1.
    Yuan Z; Tie A; Tarnopolsky M; Bakovic M
    Physiol Genomics; 2006 Jun; 26(1):76-90. PubMed ID: 16609143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.